Deruxtecan (Synonyms: MC-GGFG-DXD)

Cat. No.: HY-13631E Purity: 99.94%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

For research use only. We do not sell to patients.

Deruxtecan Chemical Structure

CAS No. : 1599440-13-7

Size	Price	Stock	Quantity
1 mg	USD 184	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 460	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 615	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 1230	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 1840	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Deruxtecan:

Exatecan mesylate In-stock
Deruxtecan-d₄ Get quote
Deruxtecan-d₆ Get quote
Deruxtecan-d₄-1 Get quote
Deruxtecan-d₂ Get quote
Deruxtecan-d₅ Get quote
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride Get quote
Exatecan mesylate dihydrate Get quote

9 Publications Citing Use of MCE Deruxtecan

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

View All Isoforms

Auristatin Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Purity & Documentation
References
Customer Review

Description

Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

IC₅₀ & Target

Camptothecins

In Vitro

Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

1034.05

Formula

C₅₂H₅₆FN₉O₁₃

CAS No.

1599440-13-7

Appearance

Solid

Color

White to yellow

SMILES

O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C48)=O)=O)=O)=O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light, stored under nitrogen

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

DMF : 100 mg/mL (96.71 mM; Need ultrasonic)

DMSO : 35 mg/mL (33.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9671 mL	4.8354 mL	9.6707 mL
5 mM	0.1934 mL	0.9671 mL	1.9341 mL
10 mM	0.0967 mL	0.4835 mL	0.9671 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.75 mg/mL (1.69 mM); Clear solution

This protocol yields a clear solution of ≥ 1.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (249 KB) HNMR (361 KB) RP-HPLC (221 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.

[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / DMF	1 mM	0.9671 mL	4.8354 mL	9.6707 mL	24.1768 mL
	5 mM	0.1934 mL	0.9671 mL	1.9341 mL	4.8354 mL
	10 mM	0.0967 mL	0.4835 mL	0.9671 mL	2.4177 mL
	15 mM	0.0645 mL	0.3224 mL	0.6447 mL	1.6118 mL
	20 mM	0.0484 mL	0.2418 mL	0.4835 mL	1.2088 mL
	25 mM	0.0387 mL	0.1934 mL	0.3868 mL	0.9671 mL
	30 mM	0.0322 mL	0.1612 mL	0.3224 mL	0.8059 mL
DMF	40 mM	0.0242 mL	0.1209 mL	0.2418 mL	0.6044 mL
	50 mM	0.0193 mL	0.0967 mL	0.1934 mL	0.4835 mL
	60 mM	0.0161 mL	0.0806 mL	0.1612 mL	0.4029 mL
	80 mM	0.0121 mL	0.0604 mL	0.1209 mL	0.3022 mL

Deruxtecan Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Deruxtecan1599440-13-7MC-GGFG-DXDDrug-Linker Conjugates for ADCInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Deruxtecan (Synonyms: MC-GGFG-DXD)

Customer Review

Other Forms of Deruxtecan:

Deruxtecan Related Antibodies

9 Publications Citing Use of MCE Deruxtecan

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Deruxtecan Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Deruxtecan Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report